AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|AAPL342.46-1.01 (-0.29%) ▼|ABBV283.23-2.19 (-0.77%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|
15.1 C
New York
Monday, October 19, 2026

Tag: vaccine

newssourceFORcompanycontentinformation1releasesmarket

New Force in Vaccine National Team: NHRI Spin-off ‘TaiU’ Completes US$2M Seed Round Led by MVL Seed Fund

TAIPEI, Aug. 1, 2025 /PRNewswire/ -- Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), today announced the completion...

Evidence review suggests COVID-19 vaccines safe for pregnant women and their babies

WILLOW GROVE, Pa., July 31, 2025 /PRNewswire/ -- Pregnant women are at increased risk of illness due to infection compared with other adults, so...

QuantiPath Adds Top-Tier Executives to Leadership Team Ahead of GenoPATHx Launch

DENVER, July 31, 2025 /PRNewswire/ -- QuantiPath.bio, a biotechnology company redefining food safety through precision genetic diagnostics, today announced the addition of two accomplished...

Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance

COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million.

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines

NEW YORK, July 30, 2025 /PRNewswire/ -- Eviva Partners, a nonprofit organization dedicated to strengthening public understanding of medical evidence, is proud to announce...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

Vaccines: Mythology, Ideology, and Reality, New Book by John Leake and Peter A. McCullough

NEW YORK, July 28, 2025 /PRNewswire/ -- Vaccines: Mythology, Ideology, and Reality tells the story of immunizations and the celebrated men who developed it with...

Piramal Pharma Limited Announces Results for Q1FY26

MUMBAI, India, July 28, 2025 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, and health and wellness company, today...

Elevate Your Portfolio: Top 3 Dow Stocks Women Should Watch for 2025 Success

Hey, fabulous financial friends! 🚀 Ready to shake up your investment strategy? Let's dive into why it might be time to swap those risky...

Konsortium ledet af Nordic Capital og Permira vil fremsætte kontant frivilligt anbefalet købstilbud vedrørende Bavarian Nordic

MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsVaccine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers